| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TEM.2004.05.003 |
| P8608 | Fatcat ID | release_nemvielyfnb7detoavbqwp3jta |
| P698 | PubMed publication ID | 15223052 |
| P5875 | ResearchGate publication ID | 8485470 |
| P50 | author | Daniel-G. Bichet | Q67522454 |
| Michel Bouvier | Q38326685 | ||
| P2093 | author name string | Virginie Bernier | |
| Monique Lagacé | |||
| P433 | issue | 5 | |
| P921 | main subject | molecular chaperones | Q422496 |
| P304 | page(s) | 222-228 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | Trends in Endocrinology and Metabolism | Q15265727 |
| P1476 | title | Pharmacological chaperones: potential treatment for conformational diseases | |
| P478 | volume | 15 |
| Q37149637 | 14-3-3s are potential biomarkers for HIV-related neurodegeneration |
| Q91718179 | A Pharmacochaperone-Based High-Throughput Screening Assay for the Discovery of Chemical Probes of Orphan Receptors |
| Q37038867 | A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity |
| Q35915766 | A cure for traffic jams: small molecule chaperones in the endoplasmic reticulum |
| Q35207863 | A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease |
| Q33629937 | A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor |
| Q55397197 | A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 structure and its downstream function in glioblastoma cells. |
| Q42549992 | Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors |
| Q41787738 | Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease |
| Q34087866 | Amino acid residues critical for endoplasmic reticulum export and trafficking of platelet-activating factor receptor |
| Q36317262 | Analyzing the Effects of a G137V Mutation in the FXN Gene |
| Q35661403 | Assay strategies for identification of therapeutic leads that target protein trafficking |
| Q38533943 | Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors |
| Q39944513 | Cell surface delivery and structural re-organization by pharmacological chaperones of an oligomerization-defective alpha(1b)-adrenoceptor mutant demonstrates membrane targeting of GPCR oligomers |
| Q37410011 | Chaperone-like effects of cell-permeant ligands on opioid receptors |
| Q38957269 | Chaperones as potential therapeutics for Krabbe disease. |
| Q33927508 | Chaperoning G protein-coupled receptors: from cell biology to therapeutics |
| Q36851855 | Complementation of a pathogenic IFNGR2 misfolding mutation with modifiers of N-glycosylation. |
| Q40808463 | Conformational Stability and Pathogenic Misfolding of the Integral Membrane Protein PMP22. |
| Q90409111 | Contribution of Cotranslational Folding Defects to Membrane Protein Homeostasis |
| Q42321930 | Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function |
| Q28297086 | Developing therapeutic approaches for metachromatic leukodystrophy |
| Q41486337 | ER Stress and Iron Homeostasis: A New Frontier for the UPR. |
| Q35762966 | Effects of cellular, chemical, and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporter proteins ABCB1/ABCB4. |
| Q27002907 | Emerging novel concept of chaperone therapies for protein misfolding diseases |
| Q36052285 | Endoplasmic Reticulum Stress and Unfolded Protein Response Pathways: Potential for Treating Age-related Retinal Degeneration |
| Q37786731 | Epileptogenic ion channel mutations: From bedside to bench and, hopefully, back again |
| Q35075365 | Escorts take the lead molecular chaperones as therapeutic targets |
| Q39548423 | Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations |
| Q34368512 | Fabry disease - current treatment and new drug development |
| Q42426222 | Fixing cystic fibrosis by correcting CFTR domain assembly |
| Q34101729 | Functional and structural analysis of five mutations identified in methylmalonic aciduria cblB type |
| Q39839857 | Functional rescue of beta-adrenoceptor dimerization and trafficking by pharmacological chaperones |
| Q33848408 | G protein-coupled receptor sorting to endosomes and lysosomes |
| Q37829756 | G protein-coupled receptors: walking hand-in-hand, talking hand-in-hand? |
| Q34140020 | GABA acts as a ligand chaperone in the early secretory pathway to promote cell surface expression of GABAA receptors |
| Q64932646 | Gain of Function for the SCN1A/hNav1.1-L1670W Mutation Responsible for Familial Hemiplegic Migraine. |
| Q36885398 | High-throughput screening assays for the identification of chemical probes |
| Q33275131 | High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones |
| Q39890679 | Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus |
| Q37071467 | Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine |
| Q39254537 | Induced Pluripotent Stem Cell Modeling of Gaucher's Disease: What Have We Learned? |
| Q36734894 | Inhibition of proteasome activity promotes the correct localization of disease-causing alpha-sarcoglycan mutants in HEK-293 cells constitutively expressing beta-, gamma-, and delta-sarcoglycan |
| Q42178606 | Inhibitor mediated protein degradation. |
| Q38200933 | Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators. |
| Q89621717 | Involvement of Endoplasmic Reticulum Stress in Palmitate-induced Apoptosis in HepG2 Cells |
| Q83230136 | Mechanism of pharmacochaperoning in a mammalian K channel revealed by cryo-EM |
| Q24299159 | Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channels in human long QT syndrome |
| Q81421178 | Modulatory proteins can rescue a trafficking defective epileptogenic Nav1.1 Na+ channel mutant |
| Q92989928 | Molecular Mechanisms and Determinants of Innovative Correction Approaches in Coagulation Factor Deficiencies |
| Q37238669 | Molecular and functional characterization of polymorphisms in the secreted phospholipase A2 group X gene: relevance to coronary artery disease |
| Q80400955 | Molecular chaperones: the modular evolution of cellular networks |
| Q26800090 | Molecular pathophysiology and pharmacology of the voltage-sensing module of neuronal ion channels |
| Q37351126 | Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function. |
| Q36825595 | N-glycan structure dictates extension of protein folding or onset of disposal |
| Q36580003 | N-linked glycan recognition and processing: the molecular basis of endoplasmic reticulum quality control |
| Q42705597 | Neuroprotection by Endoplasmic Reticulum Stress-Induced HRD1 and Chaperones: Possible Therapeutic Targets for Alzheimer's and Parkinson's Disease |
| Q36646889 | New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy |
| Q37256074 | Nonfunctional NaV1.1 familial hemiplegic migraine mutant transformed into gain of function by partial rescue of folding defects |
| Q34685511 | Norepinephrine deficiency is caused by combined abnormal mRNA processing and defective protein trafficking of dopamine beta-hydroxylase |
| Q28478533 | Novel patient cell-based HTS assay for identification of small molecules for a lysosomal storage disease |
| Q40123566 | Opioid receptor pharmacological chaperones act by binding and stabilizing newly synthesized receptors in the endoplasmic reticulum |
| Q37860332 | Pharmacological chaperone therapy for Gaucher disease: a patent review. |
| Q35606973 | Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors |
| Q42414938 | Pharmacological chaperoning: two 'hits' are better than one. |
| Q21131288 | Pharmacoperone Identification for Therapeutic Rescue of Misfolded Mutant Proteins |
| Q50014672 | Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases |
| Q26992276 | Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors |
| Q34556955 | Phenylalanine hydroxylase misfolding and pharmacological chaperones. |
| Q41955759 | Phosphorylation-dependent C-terminal binding of 14-3-3 proteins promotes cell surface expression of HIV co-receptor GPR15. |
| Q39333514 | Plasma membrane expression of gonadotropin-releasing hormone receptors: regulation by peptide and nonpeptide antagonists |
| Q47422775 | Potential Pharmacological Chaperones for Cystathionine Beta-Synthase-Deficient Homocystinuria |
| Q36510038 | Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulator. |
| Q58450753 | Protein Trafficking Diseases |
| Q39097864 | Protein aggregation, misfolding and consequential human neurodegenerative diseases. |
| Q48092471 | Protein folding: Illuminating chaperone activity |
| Q36501365 | Protein misfolding disorders: pathogenesis and intervention |
| Q46290614 | Proteostatic Tactics in the Strategy of Sterol Regulation |
| Q46525116 | RIC-3 affects properties and quantity of nicotinic acetylcholine receptors via a mechanism that does not require the coiled-coil domains |
| Q36316416 | Refolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro |
| Q46136957 | Rescuing proteins of low kinetic stability by chaperones and natural ligands phenylketonuria, a case study |
| Q37333770 | Retinitis pigmentosa mutants provide insight into the role of the N-terminal cap in rhodopsin folding, structure, and function |
| Q36610269 | Saccharomyces cerevisiae Apn1 mutation affecting stable protein expression mimics catalytic activity impairment: implications for assessing DNA repair capacity in humans |
| Q51036230 | Specific inhibition of hamster prion protein translocation by the dodecadepsipeptide valinomycin. |
| Q38092216 | Specificity and regulation of the endoplasmic reticulum-associated degradation machinery |
| Q36791174 | Stress-induced rearrangements of cellular networks: Consequences for protection and drug design |
| Q52578645 | Structural determinants for ligand-receptor conformational selection in a peptide G protein-coupled receptor. |
| Q35199497 | Structurally distinct ligands rescue biogenesis defects of the KATP channel complex via a converging mechanism |
| Q39896634 | The ART-Rsp5 ubiquitin ligase network comprises a plasma membrane quality control system that protects yeast cells from proteotoxic stress |
| Q28539680 | The influence of chemical chaperones on enzymatic activity under thermal and chemical stresses: common features and variation among diverse chemical families |
| Q39931614 | The majority of adrenocorticotropin receptor (melanocortin 2 receptor) mutations found in familial glucocorticoid deficiency type 1 lead to defective trafficking of the receptor to the cell surface. |
| Q28077257 | The relationship between glucocerebrosidase mutations and Parkinson disease |
| Q38039520 | The roles played by highly truncated splice variants of G protein-coupled receptors |
| Q38211124 | The therapeutic potential of chemical chaperones in protein folding diseases. |
| Q21089948 | Therapeutic rescue of misfolded mutants: validation of primary high throughput screens for identification of pharmacoperone drugs |
| Q39078944 | Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations |
| Q36501370 | Therapy through chaperones: sense or antisense? Cystic fibrosis as a model disease |
| Q38454078 | Traffic jam at the sodium channel |
| Q28755163 | Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease |
| Q37627277 | Trafficking and signalling of gonadotrophin-releasing hormone receptors: an automated imaging approach |
| Q26829715 | Trafficking mechanisms underlying neuronal voltage-gated ion channel localization at the axon initial segment |
| Q36594595 | Trafficking of G protein-coupled receptors |
| Q33699210 | Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs |
| Q33717398 | Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens. |
| Q39647606 | Trimethylamine-N-oxide switches from stabilizing nature: A mechanistic outlook through experimental techniques and molecular dynamics simulation |
| Q54945677 | Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones. |
| Q36697237 | Unfolding the Therapeutic Potential of Chemical Chaperones for Age-related Macular Degeneration |
| Q36909424 | Using EGFP fusions to monitor the functional expression of GPCRs in the Drosophila Schneider 2 cells |
| Q34494645 | Using automated imaging to interrogate gonadotrophin-releasing hormone receptor trafficking and function. |
| Q35093167 | WNTS and WNT receptors as therapeutic tools and targets in human disease processes. |
| Q34412182 | αA-Crystallin-derived mini-chaperone modulates stability and function of cataract causing αAG98R-crystallin |
Search more.